David Scheinberg
Director/Board Member at SELLAS LIFE SCIENCES GROUP, INC.
Net worth: 6 461 $ as of 2024-05-30
David Scheinberg active positions
| Companies | Position | Start | End |
|---|---|---|---|
| SELLAS LIFE SCIENCES GROUP, INC. | Director/Board Member | 2017-11-30 | - |
| Independent Dir/Board Member | 2017-11-30 | - | |
Sapience Therapeutics, Inc.
 Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | Director/Board Member | - | - |
| Gerstner Sloan Kettering Graduate School of Biomedical Science | Corporate Officer/Principal | - | - |
Sellas Life Sciences Group Ltd.
 Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Director/Board Member | 2017-12-28 | - |
Tri-Institutional Therapeutics Discovery Institute, Inc.
 Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Director/Board Member | - | - |
| Founder | - | - | |
| Lauri Strauss Leukemia Foundation | Corporate Officer/Principal | - | - |
| Sloan-Kettering Institute for Cancer Research | Corporate Officer/Principal | 1985-12-31 | - |
| Weill Cornell Medical College | Corporate Officer/Principal | 2010-06-08 | - |
| Commonwealth Cancer Consortium, Inc. | Director/Board Member | - | - |
Career history of David Scheinberg
Former positions of David Scheinberg
| Companies | Position | Start | End |
|---|---|---|---|
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░░░░░ ░░░░░░░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░░░░░ ░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░ ░░░░░░░░░░░░░░ | ░░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ | |
| ░░░░░░ ░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - | - |
| ░░░░░░ ░░░░ ░░░░░░░░ ░░░░░░ ░░░░ ░░░░░ | ░░░░░░░░░░░░░░ ░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░ ░░░░░ ░░░░░░░░░ ░░░░░░ ░░░░░░ | ░░░░░░░ | ░░░░░░░░░░ | - |
| ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ | - |
Training of David Scheinberg
| Cornell University | Undergraduate Degree |
| The Johns Hopkins University School of Medicine | Doctorate Degree |
Statistics
International
| United States | 16 |
| Bermuda | 2 |
| India | 2 |
Operational
| Director/Board Member | 8 |
| Corporate Officer/Principal | 6 |
| Independent Dir/Board Member | 3 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 5 |
| Health Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| CONTRAFECT CORPORATION | Health Technology |
| SELLAS LIFE SCIENCES GROUP, INC. | Health Technology |
| Private companies | 11 |
|---|---|
Progenics Pharmaceuticals, Inc.
 Progenics Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Progenics Pharmaceuticals, Inc. engages in the development of medicines and other products for targeting and treating cancer. Its pipeline includes therapeutic agents, imaging agents for prostate cancer, and imaging analysis technology. The company was founded by Paul J. Maddon on December 1, 1986 and is headquartered in New York, NY. | Health Technology |
Memorial Sloan Kettering Cancer Center
 Memorial Sloan Kettering Cancer Center Hospital/Nursing ManagementHealth Services Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY. | Health Services |
| Sloan-Kettering Institute for Cancer Research | |
| Lauri Strauss Leukemia Foundation | |
Tri-Institutional Therapeutics Discovery Institute, Inc.
Tri-Institutional Therapeutics Discovery Institute, Inc. Miscellaneous Commercial ServicesCommercial Services Part of Memorial Sloan Kettering Cancer Center, Tri-Institutional Therapeutics Discovery Institute, Inc. is an American New York-based company that encourages the Tri-Institutional community to advance their biological discoveries to preclinical studies. The company provides technical support for academic projects and offers a menu of services to translate research discoveries from bench to bedside. Tri-Institutional Therapeutics Discovery Institute achieves its mission by leveraging the infrastructure, staff, and intellectual capital of its academic and industry partners, as well as the generous support of philanthropists. The company was founded by David A. Scheinberg. | Commercial Services |
Sapience Therapeutics, Inc.
Sapience Therapeutics, Inc. BiotechnologyHealth Technology Sapience Therapeutics, Inc. focuses on advancing novel therapeutics for major unmet medical needs, particularly high mortality cancers. Its drug development program involves translating science into novel therapies, and initial goal is to develop a first-in-class treatment for glioblastoma multiforme, which is the most severe and deadly form of brain cancer. The company was founded by Barry Kappel and Isaac Blech in 2015 and is headquartered in Scarsdale, NY. | Health Technology |
SELLAS Life Sciences Group, Inc. /Old/
 SELLAS Life Sciences Group, Inc. /Old/ BiotechnologyHealth Technology SELLAS Life Sciences Group, Inc. /Old/ is based in New York, NY. SELLAS Life Sciences Group, Inc. is a clinical-stage biopharmaceutical company. | Health Technology |
Sellas Life Sciences Group Ltd.
Sellas Life Sciences Group Ltd. Pharmaceuticals: MajorHealth Technology Sellas Life Sciences Group Ltd. manufactures pharmaceutical products. It focuses on innovative products to treat cancer and central nervous system diseases. The firm’s product candidate, licensed from Memorial Sloan-Kettering Cancer Center is a late-stage innovative WT1-targeting synthetic heteroclitic epitope immunotherapeutic in development for hematological malignancies and solid tumors characterized by an overexpression of the WT1 (Wilms Tumor Protein) antigen. The company was founded by Angelos M. Stergiou in 2012 and is headquartered in Zug, Switzerland. | Health Technology |
| Centre of Nanotechnology | |
Global Positioning System
 Global Positioning System Telecommunications EquipmentElectronic Technology Global Positioning System (GPS) is a government-operated satellite-based navigation system that provides location and time information. The private company is based in Woburn, MA. The GPS modernization program has added new civil signals to the system, including the L2C and L5 signals. The ground control and space segments of the GPS are also described on the gps.gov website. The website provides information about GPS accuracy and potential interference from other communication networks. Additionally, the website offers public information in Arabic and Mandarin Chinese about the GPS. The National Aeronautics and Space Administration (NASA) also holds meetings of the National Space-Based Positioning, Navigation and Timing (PNT) Advisory Board to discuss GPS-related topics. | Electronic Technology |
| Commonwealth Cancer Consortium, Inc. |
- Stock Market
- Insiders
- David Scheinberg
- Experience
